Impact of ART Adherence on HIV Persistence and Inflammation

Understanding whether the size and dynamics of the HIV reservoir are associated with
adherence, measured by an objective biomarker, could have significant clinical and
therapeutic implications for ART and HIV cure.

1. First, this aim will quantify levels of CA-RNA, CA-DNA, and plasma residual viremia in
suppressed, HIV infected individuals and correlate them with levels of TFV-DP in DBS as
a measure of cumulate drug exposure (adherence).

2. Second, this study will evaluate the changes in the HIV reservoir in relation to changes
in ART adherence over time.

Inclusion Criteria:

1. HIV-infected males and females,

2. Ages 18 years and older,

3. Taking any TFV-based regimen,

4. HIV suppression <20 copies/ml for at least 12 months;

5. Not co-infected with HCV;

6. Able and willing to give informed consent.

Exclusion Criteria:

1. Pregnancy.

2. Refusal to participate.